Page last updated: 2024-08-23

simvastatin and Benign Neoplasms

simvastatin has been researched along with Benign Neoplasms in 50 studies

Research

Studies (50)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	21 (42.00)	29.6817
2010's	20 (40.00)	24.3611
2020's	9 (18.00)	2.80

Authors

Authors	Studies
Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L	1
Chavez-Blanco, A; Correa-Basurto, J; Dominguez-Gomez, G; Duenas-Gonzalez, A; Garcia-Martinez, E; Gonzalez-Fierro, A; Romo-Perez, A; Taja-Chayeb, L	1
Chmielarz, M; Palko-Łabuz, A; Środa-Pomianek, K; Teisseyre, A; Uryga, A	1
Guan, Z; Huang, J; Leng, H; Ren, X; Song, C; Wang, H; Yuan, W; Zhang, C; Zhang, W; Zhu, J	1
Chen, H; Gao, X; Li, J; Li, Y; Liu, J; Liu, P; Ren, Y; Song, S; Wang, B; Wang, H; Wang, R; Wang, Y; Zhang, M	1
Bjørnstad, R; Herfindal, L; Knudsen, KS; Reiten, IN; Schjøtt, J	1
Hu, Z; Li, X; Peng, C; Qiao, X; Wang, D; Xiong, F; Yang, Y	1
Chen, X; Chen, Y; Dai, Y; Jacobson, O; Niu, G; Sang, W; Shao, M; Shen, Z; Wang, J; Wang, Y; Wang, Z; Yang, Z	1
Ahangari Cohan, R; Akbarzadeh, I; Bakhshandeh, H; Noorbazargan, H; Norouzian, D; Saffar, S; Saremi Poor, A; Yaghmaei, S	1
Rao, PS; Rao, US	1
de Barros, ALB; Duarte, JA; Leite, EA	1
Baiano, S; Carnuccio, R; De Cicco, R; Fuggetta, MP; Morelli, A; Morelli, F; Tatè, R; Trotta, V; Urciuoli, M; Zona, E	1
Ballard, P; Pilla Reddy, V; Sharma, P; Vishwanathan, K; Walker, M	1
Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG	1
Anker, SD; Doehner, W; Flach, VC; Palus, S; Springer, J; Tschirner, A; von Haehling, S	1
Ay, C; Königsbrügge, O; Lötsch, F; Pabinger, I; Posch, F; Zielinski, C	1
Basta, N; Bolin, K; Busch-Sørensen, M; Egstrup, K; Emneus, M; Green, A; Iachina, M; Kent, C; Kesäniemi, YA; McNally, R; Pedersen, TR; Ramey, DR; Ray, S; Stavem, K; Willenheimer, R	1
Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J	1
Gerner, C; Grunt, T; Haider, F; Karlic, H; Proestling, K; Thaler, R; Varga, F	1
Atil, B; Bardy, J; Berger-Sieczkowski, E; Hohenegger, M; Werner, M	1
Xiao, H; Yang, CS	1
Ravnskov, U	2
Baigent, C; Califf, R; Clare, R; Collins, R; Emberson, J; Landray, M; Peto, R	1
Curfman, GD; D'Agostino, RB; Drazen, JM; Morrissey, S; Ware, JH	1
Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Bärwolf, C; Holme, I; Kesäniemi, YA; Malbecq, W; Nienaber, CA; Pedersen, TR; Ray, S; Rossebø, AB; Skjaerpe, T; Wachtell, K; Willenheimer, R	1
Struthers, M	1
Fleming, TR	1
Cox, A	1
Blazing, MA; Califf, RM; Harrington, RA	1
Nissen, SE; Taylor, AJ	1
Choi, HK; Hur, GY; In, KH; Jung, KH; Kang, KH; Kim, HO; Kim, JH; Lee, KJ; Lee, SY; Moon, JY; Shim, JJ; Shin, C; Yoo, SH	1
Drazen, JM; Wood, AJ	1
Kim, PS; Rosenblatt, M	1
Rennert, G	1
Baiano, S; Cartenì, M; De Maria, S; Giordano, E; Morelli, F; Sarnataro, M; Spampanato, C; Zanfardino, M	1
Chakraborty, K; Harirforoosh, S; Hsi, L; Krishnan, K; Menter, DG; Newman, RA; Ramsauer, VP; Yang, P	1
Prasad, V; Vandross, A	1
Bing, N; de Souza, PL; Goodman, VL; King, KS; McCann, LA; Mooser, VE; Pandite, LN; Spraggs, CF; Xu, CF; Xue, Z	1
Kim, CW; Kim, YN; Li, YC; Park, MJ; Ye, SK	1
Aggarwal, BB; Ahn, KS; Sethi, G	1
Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV	1
Chan, J; Flick, ED; Friedman, GD; Habel, LA; Quesenberry, CP; Udaltsova, N	1
Brophy, MT; Farwell, WR; Fiore, LD; Gaziano, JM; Lawler, EV; Lew, RA; Scranton, RE	1
Berg, K; Cook, TJ; Faergeman, O; Haghfelt, T; Kjekshus, J; Kristianson, J; Miettinen, T; Olsson, AG; Pedersen, TR; Pyörälä, K; Strandberg, TE; Thorgeirsson, G; Troedsson, L; Wedel, H; Wilhelmsen, L	1
Garrett, IR; Gutierrez, G; Mundy, GR	1
Platts, J	1

Reviews

7 review(s) available for simvastatin and Benign Neoplasms

Article	Year
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature cell biology, 2015, Volume: 17, Issue:11 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction	2015
Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy. Lipids in health and disease, 2023, Mar-31, Volume: 22, Issue:1 Topics: Humans; Lipid Metabolism; Macrophages; Neoplasms; Simvastatin; Tumor Microenvironment; Tumor-Associated Macrophages	2023
The potential use of simvastatin for cancer treatment: A review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 141 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Simvastatin	2021
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American heart journal, 2019, Volume: 210 Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment	2019
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac	2008
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. Journal of the American College of Cardiology, 2007, Jul-31, Volume: 50, Issue:5 Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin	2007
Statins and bone formation. Current pharmaceutical design, 2001, Volume: 7, Issue:8 Topics: Animals; Bone Development; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lovastatin; Neoplasms; Nitric Oxide Synthase; Pyridines; Simvastatin	2001

Trials

6 trial(s) available for simvastatin and Benign Neoplasms

Article	Year
Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. The American journal of cardiology, 2014, Nov-15, Volume: 114, Issue:10 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Neoplasms; Registries; Retrospective Studies; Risk Assessment; Simvastatin; Survival Rate; Time Factors	2014
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. The Canadian journal of cardiology, 2015, Volume: 31, Issue:3 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left	2015
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticholesteremic Agents; Aortic Valve Stenosis; Aspartate Aminotransferases; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Bypass; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Kaplan-Meier Estimate; Male; Neoplasms; Simvastatin; Treatment Outcome	2008
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (London, England), 2011, Dec-10, Volume: 378, Issue:9808 Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Neoplasms; Simvastatin; Stroke	2011
The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC medicine, 2005, Mar-16, Volume: 3 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cause of Death; Cholesterol; Cholesterol, LDL; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mortality; Neoplasms; Simvastatin; United Kingdom; Vascular Diseases	2005
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. The American journal of cardiology, 2000, Aug-01, Volume: 86, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Cause of Death; Coronary Artery Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Neoplasms; Risk; Scandinavian and Nordic Countries; Simvastatin; Survival Rate	2000

Other Studies

37 other study(ies) available for simvastatin and Benign Neoplasms

Article	Year
BAPST. A Combo of Common Use Drugs as Metabolic Therapy for Cancer: A Theoretical Proposal. Current molecular pharmacology, 2022, Volume: 15, Issue:6 Topics: Apomorphine; Benserazide; Drug Combinations; Humans; Neoplasms; Pantoprazole; Simvastatin; Trimetazidine	2022
Co-Application of Statin and Flavonoids as an Effective Strategy to Reduce the Activity of Voltage-Gated Potassium Channels Kv1.3 and Induce Apoptosis in Human Leukemic T Cell Line Jurkat. Molecules (Basel, Switzerland), 2022, May-18, Volume: 27, Issue:10 Topics: Apoptosis; Cell Line; COVID-19; Flavonoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kv1.3 Potassium Channel; Neoplasms; Simvastatin	2022
Single-intraosseous simvastatin injection suppresses cancers via activating CD8 Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 155 Topics: Antigens, Neoplasm; CD8-Positive T-Lymphocytes; CTLA-4 Antigen; Hepatitis A Virus Cellular Receptor 2; Humans; Neoplasms; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell; Simvastatin	2022
Metformin and simvastatin synergistically suppress endothelin 1-induced hypoxia and angiogenesis in multiple cancer types. Cancer science, 2023, Volume: 114, Issue:2 Topics: Animals; Cell Line, Tumor; Endothelin-1; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Metformin; Mice; Neoplasms; Neovascularization, Pathologic; Simvastatin	2023
A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect. International journal of pharmaceutics, 2022, Dec-15, Volume: 629 Topics: Animals; Cardiotoxicity; Doxorubicin; Liposomes; Male; Neoplasms; Reactive Oxygen Species; Simvastatin; Zebrafish	2022
Polyphenol-based nanoplatform for MRI/PET dual-modality imaging guided effective combination chemotherapy. Journal of materials chemistry. B, 2019, 10-07, Volume: 7, Issue:37 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Drug Liberation; Humans; Nanoparticles; Neoplasms; Polyethylene Glycols; Simvastatin; Theranostic Nanomedicine	2019
Niosomal delivery of simvastatin to MDA-MB-231 cancer cells. Drug development and industrial pharmacy, 2020, Volume: 46, Issue:9 Topics: Liposomes; Neoplasms; Particle Size; Simvastatin	2020
Statins decrease the expression of c-Myc protein in cancer cell lines. Molecular and cellular biochemistry, 2021, Volume: 476, Issue:2 Topics: Atorvastatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Neoplasms; Proto-Oncogene Proteins c-myc; Simvastatin	2021
Simvastatin inhibits the expression of stemness‑related genes and the metastatic invasion of human cancer cells via destruction of the cytoskeleton. International journal of oncology, 2017, Volume: 51, Issue:6 Topics: Carcinoma, Embryonal; Cytoskeleton; Fluorescent Antibody Technique; Hep G2 Cells; Humans; MCF-7 Cells; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Pluripotent Stem Cells; Prenylation; Simvastatin	2017
Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. CPT: pharmacometrics & systems pharmacology, 2018, Volume: 7, Issue:5 Topics: Acrylamides; Aniline Compounds; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Drug Interactions; Humans; Itraconazole; Models, Theoretical; Neoplasms; Rifampin; Rosuvastatin Calcium; Simvastatin	2018
Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. International journal of cardiology, 2013, Oct-09, Volume: 168, Issue:4 Topics: Animals; Cachexia; Cardiac Output; Dose-Response Relationship, Drug; Heart Rate; Neoplasms; Random Allocation; Rats; Rats, Wistar; Simvastatin; Stroke Volume; Treatment Outcome	2013
Statins are associated with low risk of venous thromboembolism in patients with cancer: a prospective and observational cohort study. Thrombosis research, 2014, Volume: 134, Issue:5 Topics: Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasms; Risk Assessment; Risk Factors; Simvastatin; Venous Thromboembolism	2014
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer genetics, 2015, Volume: 208, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Epigenesis, Genetic; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Mevalonic Acid; MicroRNAs; NADP; Neoplasms; Protein Processing, Post-Translational; Simvastatin; Vitamin D	2015
In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin. Naunyn-Schmiedeberg's archives of pharmacology, 2016, Volume: 389, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 3; Cell Line, Tumor; Dolichols; Down-Regulation; Female; HEK293 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Mice; Neoplasms; Simvastatin; Tumor Burden	2016
Re: The association between statins and cancer incidence in a veterans population. Journal of the National Cancer Institute, 2008, Jul-02, Volume: 100, Issue:13 Topics: Anticholesteremic Agents; Antineoplastic Agents; Bias; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Neoplasms; Pravastatin; Prostatic Neoplasms; Simvastatin; United States; Veterans	2008
Analyses of cancer data from three ezetimibe trials. The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13 Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin	2008
Ezetimibe and cancer--an uncertain association. The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13 Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin	2008
Reasons to be cautious about cholesterol lowering drugs. BMJ (Clinical research ed.), 2008, Sep-03, Volume: 337 Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Humans; Hypercholesterolemia; Neoplasms; Simvastatin	2008
Identifying and addressing safety signals in clinical trials. The New England journal of medicine, 2008, Sep-25, Volume: 359, Issue:13 Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Simvastatin	2008
Hypercholesterolaemia: Clarifications from adverse drug reactions agency. BMJ (Clinical research ed.), 2008, Sep-16, Volume: 337 Topics: Anticholesteremic Agents; Azetidines; England; Ezetimibe; Humans; Hypercholesterolemia; Neoplasms; Risk Factors; Simvastatin; United States; United States Food and Drug Administration	2008
Premature release of data from clinical trials of ezetimibe. The New England journal of medicine, 2009, Aug-13, Volume: 361, Issue:7 Topics: Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Databases as Topic; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Registries; Simvastatin; United States	2009
Preliminary observations from preliminary trial results: have we finally had enough? Circulation. Cardiovascular quality and outcomes, 2008, Volume: 1, Issue:1 Topics: Adult; Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Surgical Procedures; Ezetimibe; Heart Failure; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Reperfusion Injury; Research Design; Simvastatin; Survival Analysis; Treatment Outcome	2008
Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clinical and experimental immunology, 2010, Volume: 161, Issue:2 Topics: Animals; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytostatic Agents; Forkhead Transcription Factors; Gene Expression; Humans; Immune Tolerance; Immunosuppressive Agents; Indoleamine-Pyrrole 2,3,-Dioxygenase; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred C57BL; Neoplasms; Simvastatin; Spleen; T-Lymphocytes, Regulatory; Transforming Growth Factor beta	2010
Don't mess with the DSMB. The New England journal of medicine, 2010, Jul-29, Volume: 363, Issue:5 Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cardiovascular Diseases; Clinical Trials Data Monitoring Committees; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hypoglycemic Agents; Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones; United States	2010
More on DSMBs. The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19 Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Industry; Ezetimibe; Humans; Neoplasms; Simvastatin; United States	2011
Bisphosphonates: beyond prevention of bone metastases. Journal of the National Cancer Institute, 2011, Dec-07, Volume: 103, Issue:23 Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Prescriptions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Recurrence, Local; Neoplasms; Receptors, Estrogen; Secondary Prevention; Simvastatin; Veterans	2011
Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. International journal of oncology, 2012, Volume: 40, Issue:4 Topics: Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; DNA Fragmentation; Down-Regulation; Gene Expression; Genes, bcl-2; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Simvastatin	2012
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PloS one, 2011, Volume: 6, Issue:12 Topics: Cell Division; Cell Line, Tumor; Chromatography, High Pressure Liquid; Fluorescent Antibody Technique; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microscopy, Fluorescence; Neoplasms; Pravastatin; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Tandem Mass Spectrometry	2011
Cardiovascular primary prevention: how high should we set the bar? Archives of internal medicine, 2012, Apr-23, Volume: 172, Issue:8 Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin	2012
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Alanine Transaminase; Anticholesteremic Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Interactions; Humans; Hypercholesterolemia; Incidence; Indazoles; Neoplasm Proteins; Neoplasms; Polymorphism, Single Nucleotide; Pyrimidines; Reference Values; Simvastatin; Sulfonamides	2012
[Statins increase the risk of cancer among the elderly]. Lakartidningen, 2003, Mar-13, Volume: 100, Issue:11 Topics: Aged; Anticholesteremic Agents; Female; Humans; Male; Neoplasms; Risk Factors; Simvastatin	2003
Statins not associated with cancer. Harvard health letter, 2004, Volume: 30, Issue:1 Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Simvastatin	2004
Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. The American journal of pathology, 2006, Volume: 168, Issue:4 Topics: Apoptosis; bcl-X Protein; beta-Cyclodextrins; Breast Neoplasms; Carcinoma, Squamous Cell; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; Cholesterol; Down-Regulation; Enzyme Activation; ErbB Receptors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Microdomains; Neoplasms; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Simvastatin	2006
Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. Journal of immunology (Baltimore, Md. : 1950), 2007, Feb-15, Volume: 178, Issue:4 Topics: Anticholesteremic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; MAP Kinase Kinase Kinases; Neoplasms; NF-kappa B; Phosphorylation; Protein Processing, Post-Translational; Simvastatin	2007
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:1 Topics: California; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Neoplasms; Risk; Risk Factors; Simvastatin	2008
The association between statins and cancer incidence in a veterans population. Journal of the National Cancer Institute, 2008, Jan-16, Volume: 100, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Odds Ratio; Pravastatin; Proportional Hazards Models; Research Design; Retrospective Studies; Simvastatin; United States; Veterans	2008
Therapy and clinical trials. Current opinion in lipidology, 2002, Volume: 13, Issue:1 Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis	2002